skip to main content

SLE — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardConnective tissue diseasesSLESCE Rheumatology

A 24-year-old woman has photosensitive rash, oral ulcers and migratory arthralgia. Examination shows there is synovitis without erosions. Investigations show ANA and anti-dsDNA are positive with low C3. Conventional therapy has been optimised and a biologic or targeted agent is being considered according to UK specialist practice. Infection screening has been completed and shared-care monitoring is in place. What is the most appropriate biologic?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Anifrolumab

Anifrolumab is the best answer because anifrolumab best matches the disease domain and escalation pathway for sle. Belimumab is a plausible distractor, but it does not account for the key discriminator in the stem. Abatacept and Ustekinumab would be more appropriate in a different clinical pattern or at another point in the pathway, while Secukinumab is suboptimal for this presentation. Clinical pearl: biologic choice depends on disease domain, previous biologic exposure, comorbidity, infection screening and commissioning criteria.

Reference: BSR SLE guideline; EULAR SLE and systemic sclerosis recommendations; BNF